Drug intelligence / Profile preview

anti-E. coli phage cocktail

Development stage
Unknown
Lead developer
Locus Biosciences
Modality
Live Biotherapeutic Products → Microbiome Therapeutics
Administration
Oral, Intraurethral, Topical, Intravenous
01

Overview

An anti-E. coli phage cocktail is a therapeutic preparation containing a mixture of several different bacteriophages (viruses that infect and kill bacteria) specifically chosen for their ability to target and destroy various strains of *Escherichia coli*. [2, 5, 7] This approach, a form of phage therapy, is being developed as an alternative or supplement to traditional antibiotics, particularly for treating infections caused by multidrug-resistant *E. coli*. [5, 7, 16] The key advantage of a phage cocktail is its high specificity; it can eliminate pathogenic *E. coli* without harming beneficial bacteria in the host's microbiome, such as the gut flora. [1, 2, 7] This specificity also reduces the side effects commonly associated with broad-spectrum antibiotics. [5] By combining multiple phages, a cocktail can target a wider range of bacterial strains and may help to prevent the emergence of phage-resistant bacteria. [24] Some advanced cocktails, like LBP-EC01 and SNIPR001, are engineered using CRISPR-Cas technology to enhance their bacterial-killing efficacy. [3, 10, 13] Anti-E. coli phage cocktails are under investigation for various indications, including urinary tract infections (UTIs), Crohn's disease, and food safety applications. [3, 6, 20]

Brand names
EcoShield
Other names
bacteriophage cocktailphage therapy
02

Targets

bacterial dsDNA (Bacterial double-stranded DNA)OmpC (Outer membrane porin C)

Beyond the preview

Go deeper on anti-E. coli phage cocktail.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-E. coli phage cocktail.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call